Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Nonsmall Cell Lung Cancer

Hasturk S., Hatabay N., Ece F., Karatasli M., HANTA İ.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.32, no.3, pp.280-285, 2009 (SCI-Expanded) identifier identifier identifier


Objectives: Currently, cisplatin-based doublet combinations are accepted to be the first-line chemotherapy for advanced nonsmall cell lung cancer (NSCLC). Although triplet chemotherapeutics have been shown to be more effective and active than doublets, their toxicity was higher as expected. Therefore, we conducted this phase 11 trial using the combination of gemcitabine-cisplatin-vinorelbine with lower than usual but acceptable doses of gemcitabine and cisplatin to obtain higher response rate than doublet but less toxicity than triplet combinations.